Once-a-day stimulant is safe for ADHD, can be used after 1 year

Published Date: 13 Mar 2023

New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.

Read Full News

Latest News

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Reframing Dyslexia: Ancient Genes, Modern Skill

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults With IDDs Face ‘Mental Health Crisis’

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Todays Updates

Neoadjuvant GOLP Boosts Event-Free Survival in Liver Cancer

A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and toripalimab in patients with high-risk intrahepatic cholangiocarcinoma.

Risk Factors Driving Severe Maternal Morbidity in the US

Hypertensive disorders of pregnancy, chronic hypertension, and obesity are the primary risk factors for severe maternal morbidity.

CUD, Depression Share Bidirectional Link

Cannabis use disorder has a bidirectional and clinically meaningful association with major depressive disorder, new research suggests.

Medicaid Expansion Tied to Pancreatic Cancer Survival

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic cancer.

Can Upadacitinib Improve Sleep Quality in Patients With RA?

Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.

Novel Drug Duo Preserves Bladder in Muscle-Invasive Cancer

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant sacituzumab govitecan plus pembrolizumab, the SURE-02 trial finds.

Exploring Whether GLP-1 Medications May Cause Sinusitis

Research is limited, but what has been done shows a possible connection.

Todays Updates

Neoadjuvant GOLP Boosts Event-Free Survival in Liver Cancer

A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and toripalimab in patients with high-risk intrahepatic cholangiocarcinoma.

Risk Factors Driving Severe Maternal Morbidity in the US

Hypertensive disorders of pregnancy, chronic hypertension, and obesity are the primary risk factors for severe maternal morbidity.

CUD, Depression Share Bidirectional Link

Cannabis use disorder has a bidirectional and clinically meaningful association with major depressive disorder, new research suggests.

Medicaid Expansion Tied to Pancreatic Cancer Survival

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic cancer.

Can Upadacitinib Improve Sleep Quality in Patients With RA?

Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.

Novel Drug Duo Preserves Bladder in Muscle-Invasive Cancer

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant sacituzumab govitecan plus pembrolizumab, the SURE-02 trial finds.

Exploring Whether GLP-1 Medications May Cause Sinusitis

Research is limited, but what has been done shows a possible connection.

Latest News

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

News All Time

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education Charuta Joshi, MD, Isabella Ciccone, MPH

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

Recommended News For You

Unified Neuro/Psych Residency Program: New Proposal.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

New protein target discovered for childhood medulloblastomas

Recommended Articles For You

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs 

Navigating the Complexity of Peritoneal Carcinomatosis: A Guide for Patients and Caregivers 

Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies 

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists discover the 'roadmap' that aggressive cancer uses to spread

2.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

3.

Who Bears the Cost of "Forever Chemical" Cleanup?

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

1.

A New Hope: Exploring the Benefits of Exenteration for Cancer Patients

2.

Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians

3.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

4.

Understanding the Importance of Knowing Your MCV Normal Range

5.

Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

2.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

3.

Navigating the Complexities of Ph Negative ALL - Part XIII

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot